JP2024547071A5 - - Google Patents

Info

Publication number
JP2024547071A5
JP2024547071A5 JP2024537092A JP2024537092A JP2024547071A5 JP 2024547071 A5 JP2024547071 A5 JP 2024547071A5 JP 2024537092 A JP2024537092 A JP 2024537092A JP 2024537092 A JP2024537092 A JP 2024537092A JP 2024547071 A5 JP2024547071 A5 JP 2024547071A5
Authority
JP
Japan
Prior art keywords
nucleosides
gapmer oligonucleotide
antisense gapmer
oligonucleotide according
tna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024547071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/086286 external-priority patent/WO2023117738A1/en
Publication of JP2024547071A publication Critical patent/JP2024547071A/ja
Publication of JP2024547071A5 publication Critical patent/JP2024547071A5/ja
Pending legal-status Critical Current

Links

JP2024537092A 2021-12-20 2022-12-16 トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法 Pending JP2024547071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21215919.8 2021-12-20
EP21215919 2021-12-20
PCT/EP2022/086286 WO2023117738A1 (en) 2021-12-20 2022-12-16 Threose nucleic acid antisense oligonucleotides and methods thereof

Publications (2)

Publication Number Publication Date
JP2024547071A JP2024547071A (ja) 2024-12-26
JP2024547071A5 true JP2024547071A5 (cg-RX-API-DMAC10.html) 2025-12-22

Family

ID=78957536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537092A Pending JP2024547071A (ja) 2021-12-20 2022-12-16 トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法

Country Status (5)

Country Link
US (1) US20240336920A1 (cg-RX-API-DMAC10.html)
EP (1) EP4453206A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024547071A (cg-RX-API-DMAC10.html)
CN (1) CN118434860A (cg-RX-API-DMAC10.html)
WO (1) WO2023117738A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4332221A1 (en) * 2022-08-29 2024-03-06 Roche Innovation Center Copenhagen A/S Threose nucleic acid antisense oligonucleotides and methods thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
EP2284269B1 (en) 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense design
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
EP2410053B2 (en) 2006-10-18 2020-07-15 Ionis Pharmaceuticals, Inc. Antisense compounds
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2818024C (en) 2010-12-06 2019-09-24 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
AU2012223366B2 (en) 2011-03-03 2017-02-23 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US20140303235A1 (en) 2011-08-11 2014-10-09 Isis Pharmaceuticals, Inc. Linkage modified gapped oligomeric compounds and uses thereof
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013179292A1 (en) 2012-05-31 2013-12-05 Qbi Enterprises Ltd. Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
EP3027223A1 (en) * 2013-07-31 2016-06-08 QBI Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
US10358643B2 (en) 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
US9765328B2 (en) * 2014-11-25 2017-09-19 Arizona Board Of Regents On Behalf Of Arizona State University Nuclease-resistant DNA analogues
WO2021177418A1 (ja) * 2020-03-04 2021-09-10 日産化学株式会社 Calm2のアンチセンスオリゴヌクレオチド

Similar Documents

Publication Publication Date Title
JP4118348B2 (ja) Gキャプ安定化したオリゴヌクレオチド
JP2025165976A5 (cg-RX-API-DMAC10.html)
EP2885312B1 (en) Method of preparing oligomeric compounds using modified capping protocols
JP4236812B2 (ja) オリゴヌクレオチド類似体
JP2005500025A5 (cg-RX-API-DMAC10.html)
JP2003012688A (ja) オリゴヌクレオチドn3’→p5’ホスホルアミデート:合成および化合物;ハイブリダイゼーションおよびヌクレアーゼ耐性特性
JP2006502694A5 (cg-RX-API-DMAC10.html)
JPH06511492A (ja) キラルリン結合を有するオリゴヌクレオチド
EP3830102B1 (en) Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
WO2002038578A1 (en) Modified nucleosides and nucleotides and use thereof
Watts The medicinal chemistry of antisense oligonucleotides
JP2024522272A5 (cg-RX-API-DMAC10.html)
US20250376684A1 (en) Threose nucleic acid antisense oligonucleotides and methods thereof
Tomori et al. Synthesis of 2′-O-[3-(N-methylsulfamoyl) propan-1-yl] ribothymidine as a potentially applicable 2′-modified nucleoside for antisense oligonucleotides
JP2025518522A5 (cg-RX-API-DMAC10.html)
EP4453206A1 (en) Threose nucleic acid antisense oligonucleotides and methods thereof
Mangla et al. Advances in the synthesis and antisense technology applications of bridged nucleic acid monomers
CN118680948B (zh) 寡核苷酸及其在抗乙型肝炎病毒中的应用
WO1995031470A2 (en) Antisense inhibitors of gene expression
EP3830101B1 (en) Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
JPWO2022250050A5 (cg-RX-API-DMAC10.html)
HK40119680A (en) Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
WO2023224108A1 (ja) ヌクレオシド誘導体及びその利用
JPWO2023112931A5 (cg-RX-API-DMAC10.html)
JP2022120380A (ja) miRNA133-b誘導体及びその利用